Aventis Taxotere sNDA schedule for 2004
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Aventis' March 18 sNDA submission for use of Taxotere in early-stage breast cancer with involved axillary lymph notes is the second of four supplements planned for 2004. The docetaxel sNDA is based on a Phase III trial showing a significant benefit for a Taxotere/doxorubicin/cyclophosphamide (TAC) regimen compared to the standard 5-fluorouracil/doxorubicin/cyclophosphamide regimen. At 55 months follow-up, TAC-treated patients showed a 30% mortality risk reduction and a 28% reduction in chance of recurrence. The early-stage breast cancer sNDA follows a Jan. 27 submission for metastatic hormone-refractory prostate cancer. Applications for advanced gastric cancer and neo-adjuvant treatment of head and neck cancer are expected by the end of 2004...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.